Dissecting the T-cell response to hordeins in coeliac disease can develop barley with reduced immunotoxicity
GJ Tanner, CA Howitt, RI Forrester, PM Campbell, JA Tye-Din, RP Anderson
Alimentary Pharmacology & Therapeutics | WILEY-BLACKWELL | Published : 2010
Awarded by Australian Grains and Research Development Corporation
Awarded by NHMRC
The authors thank Malcolm Blundell for technical assistance. Funding from the Australian Grains and Research Development Corporation, the NHMRC (grant # 361646), and a Victorian State Government Operational Infrastructure Support Grant is gratefully acknowledged. The co-operation of the Coeliac Society of Victoria and assistance of volunteers is also gratefully acknowledged. JT-D held a National Health and Medical Research Council Postgraduate Medical Scholarship and RPA holds a Lions Cancer Council Fellowship. Declaration of personal interests: GT and CH are employees of CSIRO and co-inventors of a patent pertaining to the use low gluten barley in the food and beverage industry. JT-D and RPA are employees of Melbourne Health and co-inventors of patents pertaining to the use gluten peptides in therapeutics, diagnostics and nontoxic gluten. RPA is a substantial shareholder, director and CEO of Nexpep Pty Ltd, a company developing peptide-based therapeutics and diagnostics for coeliac disease. JT-D is a shareholder and consultant to Nexpep Pty Ltd. RF is a CSIRO honorary fellow, and CH an employee of CSIRO. Declaration of funding interests: This study was funded in part by the Australian Grains and Research Development Corporation, grant no. CSP00088, and in part by the NHMRC grant # 361646, and a Victorian State Government Operational Infrastructure Support Grant.